Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)

Our Bureau

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).

Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceuticals Corporation’s Durezol®.
It is used for the following:
· Treatment of inflammation and pain associated with ocular surgery.
· Treatment of endogenous anterior uveitis.
According to IQVIA (IMS Health), Durezol® had US sales of approximately $106mn for the 12-month period ending June 2021.
The product will be available for shipping soon.


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Fitterfly, Roche, USV and Lal Path labs to launch India's largest awareness campaign for prediabetes

India is the Diabetes capital of the world with over 80 million people suffering from type 2 (lifestyle induced) diabetes. In addition, 1 in 6 Indian may have prediabetes also known as borderline diabetes. If left untreated, 75% of these cases will convert into diabetes in 5-7 years. Indians have […]

Subscribe Now